Aravive, Inc. (ARAV) Stock Analysis

Aravive, Inc. (ARAV) Healthcare & Pipeline Overview

Aravive, Inc. is a clinical-stage biopharmaceutical company specializing in oncology and fibrosis treatments, with its lead drug batiraxcept targeting the GAS6-AXL pathway. Currently in Phase III trials for ovarian cancer, Aravive seeks to address unmet medical needs through innovative protein therapeutics and strategic collaborations within the biotechnology sector.

What Is the Investment Thesis for ARAV?

Aravive's investment thesis centers on the potential of batiraxcept to address significant unmet needs in cancer treatment, particularly in platinum-resistant recurrent ovarian cancer. The ongoing Phase III clinical trial is a critical value driver, with positive results potentially leading to regulatory approval and commercialization. The company's strategic collaborations, such as those with WuXi Biologics and 3D Medicines, provide additional avenues for growth and market expansion. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding, given the company's current market capitalization of $2.95M and negative profit margin of -885.6%. Successful clinical outcomes and strategic partnerships are essential for realizing the full potential of Aravive's pipeline and driving shareholder value. The development of AVB-S6 represents a secondary value driver, offering potential upside in additional indications.

Based on FMP financials and quantitative analysis

ARAV Key Highlights

Batiraxcept is in Phase III clinical trial for platinum-resistant recurrent ovarian cancer, representing a critical milestone.

• Strategic collaboration with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis.
• License agreement with 3D Medicines Inc. to develop products containing batiraxcept for oncological diseases in Greater China.
• Developing AVB-S6, a soluble Fc-fusion protein, to block the GAS6-AXL signaling pathway.
• The company has a negative profit margin of -885.6% and gross margin of -632.6%.

Who Are ARAV's Competitors?

ARAV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ARAV's Key Strengths?

Lead product candidate, batiraxcept, in Phase III clinical trials.

• Targeted approach to cancer treatment via GAS6-AXL pathway.
• Strategic collaborations with WuXi Biologics and 3D Medicines.
• Developing AVB-S6, a soluble Fc-fusion protein, to block the GAS6-AXL signaling pathway.

What Are ARAV's Weaknesses?

Limited financial resources, with a market cap of $2.95M.

• High dependence on the success of batiraxcept.
• Negative profit and gross margins.
• Small number of employees (23).

What Could Drive ARAV Stock Higher?

Data readout from Phase III clinical trial of batiraxcept in platinum-resistant recurrent ovarian cancer.

• Progress in Phase Ib/II clinical trial of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma.
• Development of AVB-S6 program.
• Advancement of bispecific antibody program with WuXi Biologics.

What Are the Key Risks for ARAV?

Clinical trial failures for batiraxcept or AVB-S6.

• Regulatory delays or rejection of marketing applications.
• Competition from other cancer therapies.
• Need for additional funding and potential dilution.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for ARAV?

• Expansion of Batiraxcept into New Indications: Aravive has the opportunity to expand the use of batiraxcept into other cancer types where the GAS6-AXL pathway plays a significant role, such as non-small cell lung cancer and breast cancer. Each new indication represents a potential market opportunity worth hundreds of millions of dollars, with timelines dependent on clinical trial success and regulatory approval. Successful expansion would diversify Aravive's revenue streams and reduce its reliance on a single product and indication.
• Advancement of AVB-S6 Program: The development of AVB-S6, a soluble Fc-fusion protein targeting the GAS6-AXL pathway, represents another growth opportunity for Aravive. This program could potentially address a broader range of diseases beyond cancer, including fibrosis. Preclinical and clinical studies are needed to validate the efficacy and safety of AVB-S6, with a timeline of several years before potential commercialization. Successful development would broaden Aravive's pipeline and market reach.
• Strategic Partnerships and Licensing Agreements: Aravive can pursue additional strategic partnerships and licensing agreements to expand its geographic reach and access new technologies. Collaborations with larger pharmaceutical companies or specialized biotechnology firms could provide access to funding, expertise, and commercial infrastructure. These partnerships could accelerate the development and commercialization of Aravive's pipeline, with potential deals structured around milestone payments and royalties.
• Exploiting the 3D Medicines Partnership: Aravive's license agreement with 3D Medicines Inc. provides a significant growth opportunity in the Greater China region. This partnership allows 3D Medicines to develop and commercialize batiraxcept-containing products for oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. Successful commercialization in this region could generate substantial royalty revenues for Aravive, with a timeline dependent on 3D Medicines' progress and regulatory approvals.
• Development of Novel Bispecific Antibodies: The strategic collaboration with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis represents a long-term growth opportunity for Aravive. Bispecific antibodies are a rapidly growing class of therapeutics with the potential to address a wide range of diseases. Successful development of these antibodies could lead to new product candidates and revenue streams for Aravive, with a timeline of several years before potential commercialization.

What Are ARAV's Competitive Advantages?

• Proprietary technology targeting the GAS6-AXL signaling pathway.
• Patent protection for batiraxcept and AVB-S6.
• Clinical trial data demonstrating efficacy and safety.
• Strategic partnerships with WuXi Biologics and 3D Medicines.

What Does ARAV Do?

Aravive, Inc., founded in 2008 and headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for life-threatening conditions, primarily focusing on cancer and fibrosis. The company's lead product candidate, batiraxcept, is an ultrahigh-affinity decoy protein designed to target the GAS6-AXL signaling pathway, a key driver in tumor growth, metastasis, and resistance to therapy. Batiraxcept is currently undergoing a Phase III clinical trial for the treatment of platinum-resistant recurrent ovarian cancer and a Phase Ib/II clinical trial for clear cell renal cell carcinoma and pancreatic adenocarcinoma. In addition to batiraxcept, Aravive is also developing AVB-S6, a soluble Fc-fusion protein that also aims to block the activation of the GAS6-AXL signaling pathway. Aravive has established strategic collaborations to expand its research and development capabilities. This includes an agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis, and a license agreement with 3D Medicines Inc. for the development of batiraxcept-containing products for oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. Formerly known as Versartis, Inc., the company rebranded as Aravive, Inc. in October 2018 to reflect its renewed focus on oncology and fibrosis. Aravive's mission is to address unmet medical needs by developing targeted therapies that improve patient outcomes in severe diseases.

What Products and Services Does ARAV Offer?

• Develops batiraxcept, a decoy protein targeting the GAS6-AXL signaling pathway.
• Conducts Phase III clinical trials for batiraxcept in platinum-resistant recurrent ovarian cancer.
• Conducts Phase Ib/II clinical trials for batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma.
• Develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
• Collaborates with WuXi Biologics to develop novel high-affinity bispecific antibodies.
• Partners with 3D Medicines Inc. for batiraxcept development in Greater China.

How Does ARAV Make Money?

• Develops and patents novel therapeutic proteins.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from the FDA and other agencies.
• Out-licenses or co-develops products with strategic partners.
• Generates revenue through licensing fees, milestone payments, and royalties.

What Industry Does ARAV Operate In?

Aravive operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing incidence rates. Aravive's focus on the GAS6-AXL signaling pathway positions it within a targeted therapy niche, competing with other companies developing similar approaches. Success in this space requires strong clinical data, strategic partnerships, and effective commercialization strategies. The biotechnology industry is also subject to regulatory changes and pricing pressures, which can impact profitability and market access.

Who Are ARAV's Key Customers?

• Patients with platinum-resistant recurrent ovarian cancer.
• Patients with clear cell renal cell carcinoma.
• Patients with pancreatic adenocarcinoma.
• Pharmaceutical companies through licensing agreements.

The most recent 11 insider filings for Aravive, Inc. break down as 0 sales and 11 purchases. On net that is roughly 3.8M shares acquired (about $5.1M) — insiders putting money in tends to read as conviction.

Aravive, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 61.4% below estimates on average.

Aravive, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

Aravive, Inc. (ARAV) Valuation Context

Valued at $2.95M, ARAV is classified as a micro-cap stock.

Company Profile

Aravive, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Fredric N. Eshelman. ARAV has traded publicly since 2014.

ARAV Financials

ARAV Latest News

ARAV Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources